The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Cellebrite DI Ltd (NASDAQ: CLBT) was $16.62 for the day, down -0.95% from the previous closing price of $16.78. In other words, the price has decreased by -$0.95 from its previous closing price. On the day, 1.42 million shares were traded. CLBT stock price reached its highest trading level at $16.995 during the session, while it also had its lowest trading level at $16.38.
Ratios:
Our analysis of CLBT’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 37.64. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 1.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 28, 2024, Reiterated its Buy rating but revised its target price to $13.50 from $13 previously.
BofA Securities Upgraded its Neutral to Buy on February 16, 2024, whereas the target price for the stock was revised from $9 to $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 20 ’24 when RONNEN ARMON bought 9,999 shares for $16.61 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLBT now has a Market Capitalization of 3450877184 and an Enterprise Value of 3157244672. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.41. Its current Enterprise Value per Revenue stands at 9.105 whereas that against EBITDA is 51.747.
Stock Price History:
Over the past 52 weeks, CLBT has reached a high of $16.89, while it has fallen to a 52-week low of $6.36. The 50-Day Moving Average of the stock is 29.47%, while the 200-Day Moving Average is calculated to be 56.31%.
Shares Statistics:
CLBT traded an average of 1.54M shares per day over the past three months and 2198500 shares per day over the past ten days. A total of 203.23M shares are outstanding, with a floating share count of 61.22M. Insiders hold about 70.18% of the company’s shares, while institutions hold 33.94% stake in the company. Shares short for CLBT as of 1722384000 were 2601442 with a Short Ratio of 1.69, compared to 1719532800 on 2079452. Therefore, it implies a Short% of Shares Outstanding of 2601442 and a Short% of Float of 2.54.
Earnings Estimates
The market rating for Cellebrite DI Ltd (CLBT) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.09, with high estimates of $0.13 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.43 and $0.38 for the fiscal current year, implying an average EPS of $0.41. EPS for the following year is $0.37, with 7.0 analysts recommending between $0.5 and -$0.16.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $103M to a low estimate of $100M. As of the current estimate, Cellebrite DI Ltd’s year-ago sales were $84.18MFor the next quarter, 8 analysts are estimating revenue of $106.96M. There is a high estimate of $108.3M for the next quarter, whereas the lowest estimate is $104.7M.
A total of 8 analysts have provided revenue estimates for CLBT’s current fiscal year. The highest revenue estimate was $396M, while the lowest revenue estimate was $390M, resulting in an average revenue estimate of $394.23M. In the same quarter a year ago, actual revenue was $325.11MBased on 8 analysts’ estimates, the company’s revenue will be $461.51M in the next fiscal year. The high estimate is $476M and the low estimate is $450M.
